UBS Group
PMN icon

UBS Group’s ProMIS Neurosciences PMN Stock Holding History

UBS Group’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5K Sell
1,300
-150
-10% -$2.24K ﹤0.01% 8073
2025
Q4 		$9.9K Buy
1,450
+1,350
+1,350% +$13.2K ﹤0.01% 8254
2025
Q3 		$1.06K Buy
+100
New +$1.38K ﹤0.01% 9443
2024
Q2 		– Sell
-10
Closed -$478 – 9959
2024
Q1 		$478 Sell
10
-227
-96% -$11.2K ﹤0.01% 8528
2023
Q4 		$6.82K Buy
237
+233
+5,825% +$8.71K ﹤0.01% 7670
2023
Q3 		$204 Sell
4
-24
-86% -$1.56K ﹤0.01% 8705
2023
Q2 		$2.73K Buy
+28
New +$3.72K ﹤0.01% 7709
2023
Q1 		– Sell
-94
Closed -$10.2K – 10196
2022
Q4 		$10.2K Sell
94
-22
-19% -$3.08K ﹤0.01% 8562
2022
Q3 		$18K Buy
+116
New +$17.1K ﹤0.01% 7533

Other funds holding PMN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM

UBS Group's PMN Position: Q1 2026 in Review

UBS Group reduced its ProMIS Neurosciences (PMN) stake by 10% in Q1 2026, selling an estimated $2.24K and leaving 1,300 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #8073.

UBS Group first reported a position in PMN in Q3 2022 and has held it in 9 quarters since. The position peaked at $18K in Q3 2022. 25 funds tracked by Wall St. Rank hold PMN as of Q1 2026.

  • UBS Group held 1,300 shares of ProMIS Neurosciences worth $16.5K as of Q1 2026.
  • UBS Group sold 150 ProMIS Neurosciences shares in Q1 2026, an estimated $2.24K.
  • ProMIS Neurosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8073 holding.
  • UBS Group first reported a position in ProMIS Neurosciences in Q3 2022 and has held it in 9 quarters since.
  • UBS Group's ProMIS Neurosciences position peaked at $18K in Q3 2022.
  • 25 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.